Introduction


The ESC stresses that regulating tobacco products is crucial, alongside public health measures such as smoking bans, for the public’s perception of smoking as an important health hazard. This is notably the case for cardiovascular disease (CVD), the N°1 killer in Europe, responsible for the death of 1.9 million EU citizens yearly. Indeed, smoking causes 28% of CVD deaths in men aged 35 to 69 years and 13% of CVD deaths in women of the same age. Overall, CVD is estimated to cost the EU economy €195.5 billion a year.¹

The intention of the European Commission to promote the well-being of EU citizens through the revision of the TPD, is highly appreciated by the ESC. This position paper will provide the relevant scientific information on the impact of smoking on CVD and will outline recommendations for the pursuit of optimal public health protection measures within the proposed Directive.

* The European Society of Cardiology (ESC) represents over 80,000 cardiology professionals across Europe and the Mediterranean. Its mission is “to reduce the burden of cardiovascular disease in Europe”. The ESC provides an array of scientific and educational activities, such as the production and continuous updating of Clinical Practice Guidelines, the organisation of educational courses and initiatives, pan-European surveys on specific disease areas. It also organises the ESC Congress, the largest medical meeting in Europe, as well as subspecialty congresses, in conjunction with its constituent bodies. The ESC edits and publishes 9 of the world’s leading journals on cardiology.

¹ European Heart Network and European Society of Cardiology, European Cardiovascular Disease Statistics, 2012 edition
Smoking is responsible for 25% of all avoidable deaths in smokers due to diseases of the heart and circulatory system or cardiovascular diseases (CVD). Indeed, smoking is associated with increased risk of all types of CVD, including coronary heart disease (CHD), ischemic stroke, peripheral artery disease (PAD) and abdominal aortic aneurysm. For example, the relative risk of myocardial infarction in smokers below 50 years of age is five-fold higher than in non-smokers.

The risk associated with smoking is primarily related to the amount of tobacco smoked daily and to the duration. Smoking is deleterious regardless the types of tobacco (e.g. low-tar - ‘mild’ or ‘light’ - cigarettes, filter cigarettes, cigars, pipes) and the way it is smoked (e.g. waterpipe). Smokeless tobacco (e.g. snus) is also associated with a small but statistically significant increased CVD risk.

Any reduction in smoking and second-hand smoke exposure will lead to reduced cardiovascular morbidity and mortality. Estimations indicate a 30% higher risk of CVD for a non-smoker exposed to passive smoking at home or in the work place. Several studies have reported that laws making indoor workplaces and public spaces smoke-free were associated with rapid, sizeable reductions in hospitalization for acute myocardial infarction (AMI). Alike, studies show that the risk of CVD is rapidly reduced after cessation, with significant morbidity reductions reported within the first 6 months and the risk approaching the risk of never-smokers within 10–15 years.

Smoking cessation is the most cost-effective treatment of CVD and the most cost-effective prevention strategy.

ESC POSITION

INGREDIENTS & EMISSIONS

MEASUREMENT METHODS (ART.4)

The ESC welcomes the mandatory reporting system of ingredients used in tobacco products (Art. 5). However, it believes that independent testing laboratories, approved and monitored by the competent authorities in each Member State, should be carrying out or verifying the validity of data supplied by tobacco companies. Indeed,
there is overwhelming evidence that the tobacco industry will not admit use of products with increased toxicity or addictiveness.10

**REGULATION OF INGREDIENTS (ART. 6)**

The ESC strongly agrees that products with a characterising flavour should be banned from the market. Flavours improve the taste and make it easier to inhale, particularly for young people just starting to smoke.11 All tobacco products with additives (e.g. caffeine, vitamins, etc), which convey false security to consumers with regard to their impact on health or which increase the toxic or addictive effect of a tobacco product, should also be banned.

These rules should apply to all tobacco products - including cigars, cigarillos and pipe tobacco - due to their negative impact on health and regardless of the fact that these products are mostly consumed by older people.

**LABELLING & PACKAGING**

**GENERAL PROVISIONS (ART. 7)**

The display of trademarks or promotional elements must be avoided, with the rapid introduction of plain packaging in all member countries. Indeed, studies suggest that this will have a large impact on preventing young adults from trying smoking and will lead to a reduction in smoking prevalence in older consumers.1213

**TEXT WARNINGS FOR TOBACCO SMOKING (ART. 8)**

Given the burden represented by cardiovascular diseases (CVD), each unit packet and any outside packaging of tobacco for smoking should carry information on the increased risk of CVD: “Tobacco smoke increases up to 5 times the relative risk of heart disease & stroke”.

**COMBINED HEALTH WARNINGS FOR TOBACCO SMOKING (ART. 9)**

Combined health warnings are primordial and should cover at least 75% of the front and the back surfaces of packages. Evidence shows that warnings of 75% and above are significantly more effective than those of 50% and below and are particularly effective with young adults.14 For example, in Canada smoking rates amongst 15 to 19 year olds fell from 25% to 17% between the introduction of pictorial warnings and 2011.15

Also, it is crucial to have rotating combined health warnings as evidence shows that they otherwise become ‘invisible’ for the smokers, who get too used to them.16

---

17 Cigarette packet warning labels can prevent relapse: findings from the International Tobacco Control 4-Country policy evaluation cohort study. Partos TR et al. Tob Control. 2012 Apr 25
**PRODUCT DESCRIPTION (ART. 12)**

The labelling of a unit packet and any outside packaging and the tobacco product itself should not include information about tar, nicotine and carbon monoxide yields, because such labelling has made it possible to sell false security to consumers concerned about their health. Indeed, yield labels seriously mislead the consumers and provide a false basis for decision makers.\(^1\)

It is therefore strongly suggested that yield labels are replaced with general information on the dangers of tobacco smoking and consumption.

**CROSS-BORDER DISTANCE SALES OF TOBACCO PRODUCTS**

**CROSS-BORDER DISTANCE SALES OF TOBACCO PRODUCTS (ART. 16)**

Age verification mechanisms must be implemented in all Member States, not only for retail outlets engaged in distance sales, but also at the point of sale. Large economic penalties must be foreseen for retailers in case of violation.

Indeed, the protection of children/adolescents from taking up smoking is essential to the future health of Europeans. Finland and most US states have already implemented strict regulation in this field and evidence shows that low violation rates cannot be reached without penalising violators.\(^1\)\(^1\)\(^9\)\(^2\)\(^0\)

**NON-TOBACCO PRODUCTS**

**NICOTINE-CONTAINING PRODUCTS (ART. 18)**

Nicotine containing products must be tightly regulated by national authorities. In particular, all non-tobacco nicotine containing products must require medicine authorisation, namely in order to guarantee that only safe products are sold and to prevent promotion to young adults who are non-smokers.

Nicotine-containing products requiring medical authorisation should be associated to nicotine replacement therapy: as such, they should not carry health warnings, since these could mislead users attempting to quit smoking.

**ADDITIONAL RECOMMENDATIONS**

**E-Cigarettes**

A conference of the Parties to the WHO Framework Convention on Tobacco Control (FCTC) concluded that if electronic cigarettes are not banned, a two-pronged strategy – regulating them by the competent authorities in

---


\(^{19}\) K. Gallopel et al., Consumer understanding of cigarette emission labelling, http://eurpub.oxfordjournals.org/content/early/2010/07/01/eurpub.ckp087.full


each Member State as both a tobacco and a medical product – could close potential loopholes in their regulation.\textsuperscript{21}

Scientific evidence shows that:
\begin{itemize}
  \item even cartridges labelled as containing ‘no nicotine’ may contain nicotine (as well as other carcinogens and other toxic substances)\textsuperscript{22}
  \item the emitted amount of nicotine may be markedly different in the same batch
  \item brands containing flavours such as vanilla or chocolate, will attract children, with subsequent increased risk of experimenting with cigarettes or other nicotine containing products.
\end{itemize}


\textsuperscript{22} U.S. Food and Drug Administration (FDA) http://www.fda.gov/forconsumers/consumerupdates/ucm225210.htm.